pancreatic neuroendocrine tumour
Oncology · 2012–2014
4decisions
2medicines
1carried consumer input
0individual submissions
Every decision
| Medicine | Meeting | Outcome | Consumer input |
|---|---|---|---|
| everolimus Metastatic or unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (pNET). Treatment for patients who are symptomatic despite… | Mar 2014 | Recommended with restriction | input received Medical Oncology Group · Unicorn Foundation Australia · Rare Cancers Australia |
| sunitinib Initial and continuing treatment of metastatic, unresectable, well-differentiated malignant pancreatic neuroendocrine tumour (pNET) in patients who are… | Aug 2013 | Recommended | no section in document |
| everolimus initial and continuing treatment of unresectable or metastatic, well or moderately differentiated pancreatic neuroendocrine tumour (pNET) in a patient who is… | Nov 2012 | Not recommended | unclear |
| everolimus Initial and continuing treatment of unresectable or metastatic, well or moderately differentiated pancreatic neuroendocrine tumour (pNET) in patients who are… | Nov 2012 | Not recommended | unclear |
Who spoke
Medical Oncology Group · Unicorn Foundation Australia · Rare Cancers Australia
Conditions are classified by a language model from the indication text of each submission, so an individual label here can be wrong. Consumer input is read from the document's own consumer comments section: 1 of 1 decisions since 2014 carried some. Silence means no comment reached the committee through that facility, not that nobody was affected. More on how this was built.